The University of Iowa Holden Comprehensive Cancer Center (HCCC), a matrix cancer center at the University of Iowa, is applying for renewal of its Cancer Center Support grant. This is the first competitive renewal application for the HCCC. The Cancer Center at the University of Iowa was established in 1980 when it received special """"""""Center Designation"""""""" from the Iowa State Board of Regents. It was charged with coordinating and promoting cancer activities including cancer-related research, clinical care and education across the University. The Cancer Center was an NCI-designated cancer center from 1981-84, but the grant and NCI recognition were not renewed. There was a resurgence of institutional commitment to strengthening the Cancer Center in the mid 1990s. In the late 1990s, two attempts at obtaining NCI designation were unsuccessful. Dr. George Weiner was named Cancer Center Director in late 1998, and, based on a grant submitted in October 1999, the University of Iowa Cancer Center received CCSG funding and NCI designation as a Comprehensive Cancer Center in 2000. In 2001, the center was renamed the Holden Comprehensive Cancer Center (HCCC) in recognition of major support provided by the Holden family of Williamsburg, Iowa. The HCCC has continued to strengthen with significant increases in peer-reviewed research funding, philanthropy, and access to world-class research and clinical facilities. The HCCC has a growing local, regional and national profile related to cancer research and treatment. The HCCC has a growing role in the institution, and rigorous planning and evaluation activities are allowing the HCCC to continually address how it can strengthen areas of current cancer research expertise, identify potentially valuable new areas of investigation, and address important issues such as disparities in access to clinical care and clinical trials. Organizational details of the HCCC are provided in the """"""""Organizational Capabilities"""""""" portion of the """"""""Essential Characteristics"""""""" section of this proposal. Briefly, the HCCC is a matrix cancer center that draws membership from 6 colleges and 36 departments. All members are located on the same campus in Iowa City, Iowa, and all clinical activities take place at the University of Iowa Hospitals and Clinics. The HCCC is led by the HCCC Director, Dr. George Weiner, who reports to the Dean of the College of Medicine for research related issues, and to the Hospital Director and CEO for clinically related issues. The HCCC Director is assisted by a Deputy Director and 6 Associate Directors (Basic Research, Clinical Research, Population Research, Research Infrastructure, Administration and Clinical Affairs). Research programs report formally to specific Associate Directors, however because of the translational nature of each of the programs, input is provided from each of the Associate Directors into each of the programs. The primary governing body of the HCCC is the Executive Committee. This committee is composed of the Associate Directors, program leaders, and selected other leaders within the HCCC. Other active HCCC committees include the Associate Director's Committee (that serves as the space committee), the Membership Committee, Research Review Committee, Protocol Review and Monitoring Committee, Data Safety Monitoring Committee, Advocacy Committee, External Advisory Committee and the Internal Advisory Panel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-10S2
Application #
7926300
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2009-09-30
Project End
2011-09-29
Budget Start
2009-09-30
Budget End
2011-09-29
Support Year
10
Fiscal Year
2009
Total Cost
$298,623
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Scott, Aaron T; Howe, James R (2018) Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract 14:471-482
Pelletier, Daniel J; Czeczok, Thomas W; Bellizzi, Andrew M (2018) A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma. Histopathology 73:162-166
Brooks, John M; Chapman, Cole G; Schroeder, Mary C (2018) Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome. Appl Health Econ Health Policy 16:381-393
Yates, Luke A; Aramayo, Ricardo J; Pokhrel, Nilisha et al. (2018) A structural and dynamic model for the assembly of Replication Protein A on single-stranded DNA. Nat Commun 9:5447
Lynch, Thomas J; Anderson, Preston J; Rotti, Pavana G et al. (2018) Submucosal Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse Tracheal Epithelium. Cell Stem Cell 22:653-667.e5
Albright, Emily L; Schroeder, Mary C; Foster, Kendra et al. (2018) Nipple-Sparing Mastectomy is Not Associated with a Delay of Adjuvant Treatment. Ann Surg Oncol 25:1928-1935
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Link, Brian K (2018) Transformation of follicular lymphoma - Why does it happen and can it be prevented? Best Pract Res Clin Haematol 31:49-56
Guy, Christopher L; Weiss, Elisabeth; Christensen, Gary E et al. (2018) CALIPER: A deformable image registration algorithm for large geometric changes during radiotherapy for locally advanced non-small cell lung cancer. Med Phys 45:2498-2508
Riblett, Matthew J; Christensen, Gary E; Weiss, Elisabeth et al. (2018) Data-driven respiratory motion compensation for four-dimensional cone-beam computed tomography (4D-CBCT) using groupwise deformable registration. Med Phys 45:4471-4482

Showing the most recent 10 out of 1080 publications